MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
2.020
-0.020 (-0.98%)
At close: Dec 20, 2024, 4:00 PM
1.960
-0.060 (-2.97%)
After-hours: Dec 20, 2024, 7:50 PM EST
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2023. The number of employees decreased by 5 or -27.78% compared to the previous year.
Employees
13
Change (1Y)
-5
Growth (1Y)
-27.78%
Revenue / Employee
n/a
Profits / Employee
-$1,995,337
Market Cap
51.17M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13 | -5 | -27.78% |
Dec 31, 2022 | 18 | 9 | 100.00% |
Dec 31, 2021 | 9 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Singular Genomics Systems | 255 |
Cytosorbents | 186 |
Celularity | 120 |
Connect Biopharma Holdings | 81 |
IO Biotech | 68 |
Spero Therapeutics | 46 |
Elicio Therapeutics | 32 |
Iterum Therapeutics | 14 |
MAIA News
- 2 days ago - MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings - Business Wire
- 5 days ago - MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas - Business Wire
- 12 days ago - MAIA Biotechnology Announces Private Placement of Approximately $950,000 - Business Wire
- 18 days ago - MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer - Business Wire
- 6 weeks ago - MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement - Business Wire
- 6 weeks ago - MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Business Wire
- 7 weeks ago - MAIA Biotechnology Announces $2.44 Million Private Placement - Business Wire
- 2 months ago - MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics - Business Wire